Dow Rethinks its $20 Billion Saudi Chemicals Bet
Dow Inc. (DOW) is considering selling its 35% stake in Sadara Chemical, a $20 billion joint venture with Saudi Aramco, to reduce financial pressure. As of June 30, Dow had a negative investment balance of $793 million in Sadara. The venture has faced operational disruptions and financial obligations, making it a burden for Dow. A sale could improve Dow's cash flow and align with its portfolio restructuring goals.
How this was made

The 30-second read
Why it matters
Divesting the Sadara stake could materially improve Dow's cash generation and ROIC, influencing investor sentiment and valuation.
Market read
The news is material for Dow shareholders and may affect chemicals sector sentiment, with limited spillover to broader markets.
What to watch
Potential buyer terms, tax implications, and Aramco's willingness could delay or diminish benefits.
Background
Dow has been reshaping its portfolio amid a prolonged downturn in the global chemicals industry and a negative $793 million investment balance in Sadara.
Ticker impact
Dow Inc. is considering selling its 35% stake in Sadara, a $20 billion joint venture with Saudi Aramco, creating a potential divestiture.
Potential upside of 3‑5% if the sale is confirmed, with reduced downside risk.
Large stake in a loss‑making venture; removal would boost free‑cash‑flow expectations.
Market effects
Chemicals sector may see pressure relief for peers with similar joint‑venture exposures.
US equities could react positively to Dow's potential de‑risking.
Limited to Dow and chemicals industry; no broad macro effect.
Counterpoint
If the sale stalls, Dow may face continued cash‑flow strain, keeping the stock under pressure.
Key entities
- CompanyDow Inc.
U.S. chemicals maker considering stake sale.
- Joint VentureSadara Chemical
35% owned by Dow, 65% by Saudi Aramco.
- CompanySaudi Aramco
Partner in Sadara joint venture.


